Two-Drug cocktail shows promise for Tough-to-Treat melanoma
NCT ID NCT03021460
First seen Jan 22, 2026 · Last updated Jun 10, 2026 · Updated 21 times
Summary
This early-phase study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes cancer cells need to grow)—in people with advanced melanoma that cannot be removed by surgery. The main goals are to find the safest dose of ibrutinib when given with pembrolizumab and to see if the combination shrinks tumors. About 20 participants are enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.